Livzon Pharmaceutical Group Inc. (SHE:000513)
China · Delayed Price · Currency is CNY 32.67
+0.13 (0.40%)
Apr 28, 2026, 3:04 PM CST
SHE:000513 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Operating Revenue | 11,587 | 11,897 | 11,701 | 12,326 | 12,524 | 11,928 |
Other Revenue | 123.46 | 123.46 | 111.73 | 104.45 | 105.89 | 135.88 |
| 11,711 | 12,020 | 11,812 | 12,430 | 12,630 | 12,064 | |
Revenue Growth (YoY) | -0.34% | 1.76% | -4.97% | -1.58% | 4.69% | 14.67% |
Cost of Revenue | 4,000 | 4,135 | 4,249 | 4,772 | 4,577 | 4,309 |
Gross Profit | 7,710 | 7,885 | 7,564 | 7,658 | 8,053 | 7,754 |
Selling, General & Admin | 4,097 | 4,182 | 3,869 | 4,255 | 4,545 | 4,548 |
Research & Development | 891.3 | 937.95 | 1,033 | 1,335 | 1,427 | 1,146 |
Other Operating Expenses | 165.79 | 139.71 | 120.33 | 133.07 | 143.97 | 135.87 |
Operating Expenses | 5,145 | 5,259 | 5,027 | 5,736 | 6,121 | 5,837 |
Operating Income | 2,565 | 2,627 | 2,536 | 1,921 | 1,932 | 1,917 |
Interest Expense | -51.99 | -57.21 | -88.61 | -102.09 | -97.55 | -84 |
Interest & Investment Income | 334.66 | 347.65 | 265.34 | 429.98 | 359.25 | 251.81 |
Currency Exchange Gain (Loss) | -22.92 | -22.92 | 0.94 | 10.23 | 56.68 | -4.28 |
Other Non Operating Income (Expenses) | -28.87 | -5.72 | -6.98 | -4.42 | -6.37 | -4.01 |
EBT Excluding Unusual Items | 2,796 | 2,888 | 2,707 | 2,255 | 2,244 | 2,077 |
Gain (Loss) on Sale of Investments | 0.55 | 17.98 | -15.44 | -25.65 | -75.27 | -23.03 |
Gain (Loss) on Sale of Assets | -0.72 | -0.54 | 45.2 | -0.17 | 0.86 | 7.03 |
Asset Writedown | -67.71 | -73.35 | -19.86 | -2.43 | -13.99 | -6.15 |
Other Unusual Items | 27.23 | 29.49 | 89.08 | 155.76 | 174.68 | 191.12 |
Pretax Income | 2,755 | 2,862 | 2,806 | 2,383 | 2,331 | 2,246 |
Income Tax Expense | 423.76 | 451.01 | 501.66 | 485.07 | 374.97 | 293.59 |
Earnings From Continuing Operations | 2,331 | 2,411 | 2,304 | 1,898 | 1,956 | 1,952 |
Minority Interest in Earnings | -367.96 | -387.79 | -243.39 | 56.05 | -46.17 | -176.42 |
Net Income | 1,963 | 2,023 | 2,061 | 1,954 | 1,909 | 1,776 |
Net Income to Common | 1,963 | 2,023 | 2,061 | 1,954 | 1,909 | 1,776 |
Net Income Growth | -6.05% | -1.84% | 5.50% | 2.32% | 7.53% | 3.54% |
Shares Outstanding (Basic) | 891 | 893 | 920 | 929 | 935 | 935 |
Shares Outstanding (Diluted) | 891 | 893 | 920 | 931 | 936 | 936 |
Shares Change (YoY) | -2.19% | -2.96% | -1.10% | -0.56% | -0.04% | -0.25% |
EPS (Basic) | 2.20 | 2.27 | 2.24 | 2.10 | 2.04 | 1.90 |
EPS (Diluted) | 2.20 | 2.27 | 2.24 | 2.10 | 2.04 | 1.90 |
EPS Growth | -3.95% | 1.16% | 6.64% | 2.94% | 7.47% | 3.73% |
Free Cash Flow | 2,713 | 2,571 | 2,409 | 2,428 | 1,833 | 593.23 |
Free Cash Flow Per Share | 3.05 | 2.88 | 2.62 | 2.61 | 1.96 | 0.63 |
Dividend Per Share | 1.430 | 1.430 | 1.100 | 1.350 | 1.600 | 1.300 |
Dividend Growth | 30.00% | 30.00% | -18.52% | -15.63% | 23.08% | 4.00% |
Gross Margin | 65.84% | 65.60% | 64.03% | 61.61% | 63.76% | 64.28% |
Operating Margin | 21.90% | 21.85% | 21.47% | 15.46% | 15.30% | 15.89% |
Profit Margin | 16.77% | 16.83% | 17.45% | 15.72% | 15.12% | 14.72% |
Free Cash Flow Margin | 23.17% | 21.39% | 20.39% | 19.54% | 14.51% | 4.92% |
EBITDA | 3,109 | 3,173 | 3,092 | 2,740 | 2,563 | 2,342 |
EBITDA Margin | 26.54% | 26.40% | 26.18% | 22.05% | 20.29% | 19.41% |
D&A For EBITDA | 543.59 | 546.04 | 555.85 | 818.8 | 630.56 | 425.02 |
EBIT | 2,565 | 2,627 | 2,536 | 1,921 | 1,932 | 1,917 |
EBIT Margin | 21.90% | 21.85% | 21.47% | 15.46% | 15.30% | 15.89% |
Effective Tax Rate | 15.38% | 15.76% | 17.88% | 20.36% | 16.09% | 13.07% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.